IMI launches 13th call

The JTI Innovative Medicines Initiative 2 (IMI JU) has launched its thirteenth call for proposals under the IMI 2 programme. The Stage 1 submission deadline is February 28, 2018. The indicative budget available for the call with identifier H2020-JTI-IMI2-2017-13-two-stage is € 223,050,000, of which € 106,629,000 is from EFPIA companies and IMI2 Associated Partners and € 116,421,000 from the IMI2 JU.

The call includes fifteen topics:

• Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches;
• Topic 2: Genome-Environment Interactions in Inflammatory Skin Disease;
• Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use;
• Topic 4: Mitochondrial Dysfunction in Neurodegeneration;
• Topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative;
• Topic 6: A sustainable European induced pluripotent stem cell platform;
• Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice;
• Topic 8: Human tumour microenvironment immunoprofiling;
• Topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now;
• Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system;
• Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease;
• Topic 12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes;
• Topic 13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases;
• Topic 14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases;
• Topic 15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases.

Applicant consortia are invited to submit a proposal for each of the topics that are relevant for them. The proposals should address all aspects of the topic to which the applicant consortia are applying. The size and composition of each consortium should be adapted so as to respond to the scientific goals and the expected key deliverables. The IMI2 JU objectives are usually implemented through Research and Innovation Actions (RIAs), and Coordination and Support Actions (CSAs) where public and private partners collaborate, joining their expertise, knowledge and resources. 

The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).